OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
June 01, 2023
The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.
May 03, 2023
Older adults with comorbidities, including diabetes and chronic heart and lung disease, are at an increased risk of RSV hospitalization and death.
December 30, 2022
Why has this season brought an unprecedented number of severe RSV infections, and why is vaccine development taking so long?
September 23, 2022
RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.